Evaluation of sarcopenia, sarcopenic obesity, and phase angle in geriatric gastrointestinal cancer patients: before and after chemotherapy

Bıçaklı, Derya Hopancı

doi:10.3906/sag-1808-114

Cited by 22 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with metastatic urothelial carcinoma and colorectal carcinoma, BIA was deemed comparable to axial L3 CT scan imaging in estimating sarcopenia . BIA had high correlation with calf circumference and grip strength in patients with gastrointestinal neoplasia . BIA overestimated muscle mass when compared with DXA scan in patients with lung cancer .…”

Section: Resultsmentioning

confidence: 85%

“…For articles that remained after the initial screen, 65 full texts were reviewed for eligibility. Ultimately, 24 studies were selected for inclusion in the systematic review—18 articles and 6 abstracts —with a total of 3,607 patients.…”

Section: Resultsmentioning

confidence: 99%

“…Table provides an overview of included studies regarding number of study participants, cancer types, inclusion criteria, and stage of care when the BIA assessment was conducted. Cancer sites included gastric , esophageal , lung , colorectal , urothelial , and multiple . BIA assessment was conducted before surgery in 12 studies , before chemotherapy in 7 studies , and before both chemotherapy and surgery in 5 studies .…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Bioelectrical Impedance Analysis for the Assessment of Sarcopenia in Patients with Cancer: A Systematic Review

et al. 2019

View full text Add to dashboard Cite

Background. The loss of muscle mass, known as sarcopenia, is a natural process of aging that is associated with adverse health outcomes regardless of age. Because cancer is a disease of aging, interest in sarcopenia and its potential impact in multiple cancer populations has increased significantly. Bioelectrical impedance analysis (BIA) is a guideline-accepted method for sarcopenia detection. This systematic review assesses the literature pertaining to BIA use in the detection of sarcopenia in adults with cancer. Materials and Methods. In this systematic review, a search of the literature for randomized controlled trials and observational studies was conducted using MEDLINE, Cochrane CENTRAL, and EMBASE, through July 15, 2019. The study is registered at Prospero (CRD 42019130707). For study inclusion, patients had to be aged 18 years or older and diagnosed with solid or hematological neoplasia, and BIA had to be used to detect sarcopenia. Results. Through our search strategy, 5,045 articles were identified, of which 24 studies were selected for inclusion in the review (total number of 3,607 patients). In five studies, BIA was rated comparable to axial computed tomography (CT) scan, calf circumference, or grip strength for sarcopenia screening. In 14 studies, BIAidentified sarcopenia was associated with adverse clinical outcomes. Conclusion. BIA is an accurate method for detecting sarcopenia in adults with cancer prior to treatment and is a viable alternative to CT, dual-energy x-ray absorptiometry, and magnetic resonance imaging in oncology clinical practice. The Oncologist 2020;25:170-182 Implications for Practice: Bioelectrical impedance analysis (BIA) is an attractive method for identifying sarcopenic patients in clinical practice because it provides an affordable, noninvasive test that can be completed within a few minutes during a clinic visit. BIA does not require highly skilled personnel, and results are immediately available. This systematic review summarizes the literature pertaining to BIA assessment of sarcopenia in adults with cancer, with a focus on its use in diverse cancer populations.

show abstract

Section: Resultsmentioning

confidence: 85%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Bioelectrical Impedance Analysis for the Assessment of Sarcopenia in Patients with Cancer: A Systematic Review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The evaluation of muscle mass with CT is well defined and established (Cruz‐Jentoft, 2019). In various cancer types, sarcopenia has become a hot topic, as a prognostic marker and related with survival (Gokyer, 2019; Hopanci Bicakli, 2019; Ozawa, 2019). However, there is still to be learned from other various imaging modalities including metabolic imaging, FDG PET.…”

Section: Discussionmentioning

confidence: 99%

“…Survival was reported to be related with sarcopenia in patients with cancer, since survival is a measure of paramount interest in studies of all types of cancer (Gokyer, 2019; Hopanci bicakli, 2019; Nakamura, 2015, 2019; Ozawa, 2019). In our study, we observed a relation with sarcopenia and survival both in terms of CT‐based and FDG‐based metabolic evaluation, which suggested the utility of metabolic evaluation in muscle assessment in MM.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Sarcopenia with F‐18 FDG PET/CT and relation with disease outcomes in patients with multiple myeloma

et al. 2020

View full text Add to dashboard Cite

Multiple myeloma (MM) is characterised with the neoplastic production of clonal plasma cells which produce a monoclonal immunoglobulin. Accounting for 1%-2% of all cancers and more than 15% of haematological malignancies in the United States, worldwide incidence of MM is reported as 160.000/year with 106.000 deaths/year (Bray, 2018; Siegel, 2019). Median age of patients with MM at diagnosis is 66 years, and only 2% of patients are younger than 40 years. Most patients present with symptoms related with anaemia, hypercalcaemia, bone pain, renal disease and constitutional symptoms including fatigue and weight loss (Cowan, 2016). The standard of care for the bone disease of MM has evolved from plain radiographs to more sophisticated modalities, spinal magnetic resonance (MR), position emission tomography/computerised tomography (PET/CT), whole-body CT or MRI, and more recently, PET/ CT with novel agents against the pathophysiology of bone disease of MM, pentixafor PET/CT (Pan, 2020). Sarcopenia is defined as loss of skeletal muscle mass and is an important health problem generally related with ageing

show abstract

Accuracy of isolated nutrition indicators in diagnosing malnutrition and their prognostic value to predict death in patients with gastric and colorectal cancer: A prospective study

Sousa

Silva²,

Carvalho

et al. 2021

J Parenter Enteral Nutr

View full text Add to dashboard Cite

Background The study aims to evaluate the accuracy of isolated nutrition indicators in diagnosing malnutrition in patients with gastric and colorectal cancer and their association with mortality. Methods Prospective cohort study involving patients with cancer (n = 178) attending a reference center of oncology at any point in the disease trajectory or treatment. Nutrition status was evaluated in a unique moment by body mass index (BMI), Patient‐Generated Subjective Global Assessment (PG‐SGA), handgrip strength (HGS), and calf circumference (CC). Kappa coefficient, accuracy, sensitivity, specificity, positive and negative predictive values, and area under the receiver operating characteristic curve (AUC) were calculated for each nutrition indicator (PG‐SGA as the reference method). The Cox proportional hazards model was used to assess hazard ratio (HR) and CI of mortality. Results From the total patients, 11% were underweight, 48% were malnourished (PG‐SGA B or C), 43% had low HGS, and 55% presented low CC. There were 46 deaths (25.8%). BMI, HGS, and CC showed poor and fair agreements (κ < 0.30 for all ) and poor accuracy (AUC < 0.70 for all) in identifying malnutrition by PG‐SGA. After the adjustment for confounders (age, treatment performed, site, and stage of cancer), PG‐SGA (HR, 2.9; 95% CI, 1.5–5.9) and low CC (HR, 2.4; 95% CI, 1.1–5.2) were independent predictors of mortality. Conclusion The nutrition indicators are not accurate in diagnosing malnutrition, whereas PG‐SGA and low CC could predict mortality in gastric and colorectal cancer patients. Thus, CC should be combined with PG‐SGA in nutrition assessments.

show abstract

Evaluation of sarcopenia, sarcopenic obesity, and phase angle in geriatric gastrointestinal cancer patients: before and after chemotherapy

Cited by 22 publications

References 28 publications

Bioelectrical Impedance Analysis for the Assessment of Sarcopenia in Patients with Cancer: A Systematic Review

Bioelectrical Impedance Analysis for the Assessment of Sarcopenia in Patients with Cancer: A Systematic Review

Evaluation of Sarcopenia with F‐18 FDG PET/CT and relation with disease outcomes in patients with multiple myeloma

Accuracy of isolated nutrition indicators in diagnosing malnutrition and their prognostic value to predict death in patients with gastric and colorectal cancer: A prospective study

Contact Info

Product

Resources

About